Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Finished Goods (2016 - 2025)

Ocular Therapeutix has reported Finished Goods over the past 11 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Finished Goods at $1.6 million for Q4 2025, up 22.74% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 22.74% YoY), and the annual figure for FY2025 was $1.6 million, up 22.74%.
  • Finished Goods for Q4 2025 was $1.6 million at Ocular Therapeutix, down from $1.9 million in the prior quarter.
  • Over the last five years, Finished Goods for OCUL hit a ceiling of $1.9 million in Q3 2025 and a floor of $257000.0 in Q4 2021.
  • Median Finished Goods over the past 5 years was $1.0 million (2023), compared with a mean of $917900.0.
  • Biggest five-year swings in Finished Goods: crashed 61.26% in 2021 and later skyrocketed 198.05% in 2022.
  • Ocular Therapeutix's Finished Goods stood at $257000.0 in 2021, then skyrocketed by 198.05% to $766000.0 in 2022, then rose by 29.37% to $991000.0 in 2023, then skyrocketed by 34.91% to $1.3 million in 2024, then rose by 22.74% to $1.6 million in 2025.
  • The last three reported values for Finished Goods were $1.6 million (Q4 2025), $1.9 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.